Abstract
Graves ophthalmopathy is an autoimmune disease that affects the orbit and the adnexa. During the active phase, usually lasting from 6 months to 2 years, there is enlargement and fibrosis of the orbital fat and extraocular muscles, which can lead to ocular surface disease, abnormal extraocular motility, compressive optic neuropathy, and cosmetic impairment. Management can be divided into three broad categories: supportive, immunomodulatory, and reconstructive. When a patient’s disease reaches a level of severity that requires treatment beyond supportive measures such as lubrication, immunomodulatory therapies and surgical intervention may be necessary. Methods to treat the active disease include radiation and medical treatments, with steroids or the insulin-like growth factor 1 receptor inhibitor, teprotumumab, which was FDA approved in January of 2020. Reconstructive procedures may be used to manage optic nerve compression, proptosis, eyelid malposition, and ocular misalignment. In this chapter, we address presentation, diagnosis, and management of Graves ophthalmopathy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26.
Bartley GB. Rundle and his curve. Arch Ophthalmol. 2011;129(3):356–8.
Sahli E, Gunduz K. Thyroid-associated ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94–105.
Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013;5:CD009226.
Mohyi M, Smith TJ. IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol. 2018;61(1):T29–43.
Abraham-Nordling M, Byström K, Törring O, Lantz M, Berg G, Calissendorff J, Nyström HF, Jansson S, Jörneskog G, Karlsson FA, Nyström E. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165(6):899–905.
Tanda ML, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443–9.
Dolman PJ. Evaluating Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;26(3):229–48.
Shan SJC, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–85.
Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–90.
Zhao J, et al. Thyroid eye disease-related epiblepharon: a comparative case study. Asia-Pacific J Ophthal. 2020;9(1):44–7.
Victores AJ, Takashima M. Thyroid eye disease: optic neuropathy and orbital decompression. Int Ophthalmol Clin. 2016;56(1):69–79.
Fishman DR, Benes SC. Upgaze intraocular pressure changes and strabismus in Graves’ ophthalmopathy. J Clin Neuroophthalmol. 1991;11(3):162–5.
Bothun ED, et al. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543–51.
Mourits MP, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14.
Ponto KA, et al. Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology. 2011;118(11):2279–85.
Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves’ orbitopathy. J Endocrinol Invest. 2020;44(4):703–12. https://doi.org/10.1007/s40618-020-01380-9.
Takasu N, Oshiro C, Akamine H, et al. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects. J Endocrinol Investig. 1997;20(8):452–61.
Planck T, et al. Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy. Thyroid. 2014;24(10):1524–32.
Nita M, Grzybowski A. Smoking and eye pathologies. A systemic review. Part II. Retina diseases, uveitis, optic neuropathies, thyroid-associated orbitopathy. Curr Pharm Des. 2017;23(4):639–54.
Marcocci C, Kahaly GJ, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920–31.
Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2003;90(9):5234–40.
Aktaran S, Akarsu E, Erbagci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007;61(1):45–51.
Wang Y, Patel A, Douglas RS. Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305–18.
Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422–31.
Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432–41.
Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89–95.
Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves’ orbitopathy. Am J Ophthalmol Case Rep. 2017;7:146–8.
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–90.
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–61.
Douglas RS, Sile S, Thompson EHZ, et al. Teprotumumab treatment effect on proptosis in patients with active thyroid eye disease: results from a phase 3, randomized, double-masked, placebo-controlled, parallel-group, multicenter study. Proceedings American Association of Clinical Endocrinologists. Endocr Pract. 2019;25.
Douglas RS, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–52.
Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108:1523–34.
Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857–65.
Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(2):398–409.
Mourits MP, et al. (2000) Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355(9214):1505–9.
Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Investig. 1991;14(10):853–60.
Ng CM, Yuen HK, Choi KL, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med J. 2005;11(5):322–30.
Shams PN, Ma R, Pickles T, Rootman J, et al. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014;157(6):299–1305.
Rootman DB, Golan S, Pavlovich P, et al. Postoperative changes in strabismus, ductions, exophthalmometry, and eyelid retraction after orbital decompression for thyroid orbitopathy. Ophthalmic Plast Reconstr Surg. 2017;33(4):289–93.
Yoon MK, McCulley TJ. Autologous dermal grafts as posterior lamellar spacers in the management of lower eyelid retraction. Ophthal Plast Reconstr Surg. 2014;30:64–8.
Fichter N, Guthoff RF, Schittkowski MP. Orbital decompression in thyroid eye disease. ISRN Ophthalmol. 2012;2012:739236.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
McDonnell, E.C., McCulley, T.J. (2021). Graves Ophthalmopathy. In: Henderson, A.D., Carey, A.R. (eds) Controversies in Neuro-Ophthalmic Management. Springer, Cham. https://doi.org/10.1007/978-3-030-74103-7_25
Download citation
DOI: https://doi.org/10.1007/978-3-030-74103-7_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-74102-0
Online ISBN: 978-3-030-74103-7
eBook Packages: MedicineMedicine (R0)